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The incidence of tick-borne encephalitis (TBE) varies significantly over time. To better
understand the annual incidence of all TBE cases in Latvia we investigated the disease bur-
den in the country from 1973–2016 using several available sources and case definitions.
Methods
We identified cases of TBE from an electronic database (maintained by the Centre for Dis-
ease Prevention and Control of Latvia [CDPC]) by the use of ICD-10 diagnosis codes for
TBE (A84; A84.0; A84.1; A84.8; A84.9). In addition, previously unreported TBE cases were
found by review of TBE diagnoses according to ICD-10 codes in four hospital databases.
Results
From 1973 to 2016 a total of 15,193 TBE cases were reported to the CDPC, 2,819 of which
were reported from January 2007 through December 2016, additionally for this time period,
104 cases were identified via hospital survey. From all 2,923 reported cases (2007–2016),
1,973 met TBE case definition criteria and were included in the TBE study analysis. The
highest average 10 year incidence was observed from 1990–1999 (27.9 cases per 100,000;
range 4.6–53.0), however, the average 10-year incidence from 2007–2016 using officially
adopted TBE case definition was 9.6 cases per 100,000 (range 5.8–14.6). For this 10-year
time period most cases were adults (95.1%) and male (52.2%). The most common clinical
form of TBE was meningitis (90.6%). A tick bite prior to TBE onset was reported in 60.6% of
TBE cases and 98.2% of cases were not vaccinated against TBE.







Citation: Zavadska D, Odzelevica Z, Karelis G,
Liepina L, Litauniece ZA, Bormane A, et al. (2018)
Tick-borne encephalitis: A 43-year summary of
epidemiological and clinical data from Latvia (1973
to 2016). PLoS ONE 13(11): e0204844. https://doi.
org/10.1371/journal.pone.0204844
Editor: Ulrike Gertrud Munderloh, University of
Minnesota, UNITED STATES
Received: January 29, 2018
Accepted: September 14, 2018
Published: November 13, 2018
Copyright: © 2018 Zavadska et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: This clinical research collaboration study
was funded by Pfizer (WI219003) and sponsored
by Riga Stradins University and Pfizer. The funder
also provided support in the form of salaries for
authors [HJS, WE, MTTH], but did not have any
additional role in the study design, data collection
and analysis, decision to publish, or preparation of
the manuscript. The specific roles of these authors
are articulated in the ‘author contributions’ section.
Conclusion
The data demonstrate that the incidence of TBE varies by about one third based on the
case definition used. TBE occurs almost entirely in the unvaccinated population. Regular
TBE awareness campaigns could encourage the population in Latvia to use protective mea-
sures to further control TBE in the country, either via vaccination or tick avoidance.
Introduction
Tick-Borne Encephalitis (TBE) is a potentially life-threatening infectious disease that occurs in
endemic areas across the forested belt throughout Western, Central and Northern Europe
through Asia to Hokkaido island in Northern Japan.[1, 2] TBE is caused by the TBE virus
(TBEV), a flavivirus which is usually transmitted by infected ticks or in rare circumstances by
consumption of unpasteurized dairy products from infected goats, sheep or cows. The main
vectors of the TBE virus in Europe are ticks of the Ixodidae family, mainly Ixodes ricinus and
Ixodes persulcatus (the latter mainly in Eastern Europe).[3] All three main TBEV subtypes
(European, Siberian and Far-Eastern) are carried by ticks in Latvia.[4] Although the disease is
preventable by vaccination[5], it continues to be one of the most frequent causes of viral men-
ingitis/encephalitis among both visitors and the local population.[6, 7]
According to published data the number of reported TBE cases in Europe has increased by
up to 193.2% in the last 30 years.[7] The availability of improved and cheaper diagnostic tests,
increased disease awareness, increased outdoor activities and global warming all have been
hypothesized to be contributing to the observed increasing incidence and expanding geo-
graphic distribution of the TBEV, which has now become a growing public health concern in
many countries.[2, 8] In addition, reliable estimates of TBE incidence are not available in most
countries, particularly before 2012. This is largely due to differences in diagnostic criteria, case
definitions and valid and consistent reporting systems for TBE infection; all are problems
which still exist today. With these methodological limitations in mind, the true and full burden
of TBE in Europe remains unclear and likely is/has been underestimated. Therefore, in Sep-
tember 2012 the European Centre for Disease Prevention and Control (E-CDC) included TBE
on the list of notifiable diseases in the European Union, and included a case definition for eas-
ier and more uniform diagnosis.[9, 10]
Based on national legislation, there has been a countrywide mandatory case-based passive
reporting system in place in Latvia since 1973, presided over by The Centre for Disease Pre-
vention and Control (CDPC) of Latvia. However, the E-CDC case definition for TBE was not
in use in Latvia until officially adopted in 2012.[9] This definition required 3 criteria: 1) appro-
priate clinical symptoms (central nervous system [CNS] inflammation); 2) an epidemiological
link; and 3) serological confirmation. Aggregated data on TBE cases in Latvia are available
from 1955[11], but serological testing for TBE only began in the 1970’s.[12] Before 2012, the
reporting of cases in Latvia usually required only a positive serology result, and did not neces-
sarily require symptoms of CNS disease. Thus, reported TBEV infections sometimes included
those without evident CNS involvement. Since TBE became notifiable in Latvia, the reported
annual number of TBEV-infections (with or without CNS involvement) was surprisingly high.
Between 1990 and 2000 Latvia had one of the highest incidences of TBE in the world, ranging
from 8 to 53 cases per 100,000 population.[7] With more specific reporting the incidence of
TBE has decreased significantly, however Latvia still has extremely high TBE incidence rates
TBE in Latvia
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compared to other countries in Europe, and has significant differences between regions within
the country.
Vaccination remains the most effective protective measure against TBE.[5, 13, 14] The use
of anti-TBEV immunoglobulins as post-exposure prophylaxis was abandoned Europe-wide as
this method was never proven to be effective in controlled clinical trials. It has been suggested
that the application of immunoglobulins may even aggravate the clinical course, although this
has never been proven.[15, 16] Current TBE vaccines in use in Latvia include FSME-Immun
(Pfizer; formerly TicoVac, used since 1995) and Encepur (GlaxoSmithKline; available since
2001 for adults and since 2002 for children). Both vaccines were found to be highly immuno-
genic in clinical studies with close to 100% seroconversion rates after the primary vaccine
series in both adults and children.[17, 18]
Latvia has had a National TBE Immunization Program since 2006. This program provides
TBE vaccines free of charge to children living in highly endemic areas. This program has also
covered children without parental care country-wide since 2010. Before the start of the
National Immunization Program (between 1997 and 2003) there were some TBE vaccination
campaigns for children living in specific highly endemic areas that provided partial reimburse-
ment from the government and various sponsors, but these programs were not implemented
on a large scale. Vaccination against TBE is mandatory for those with a high risk of occupa-
tional exposure in Latvia, such as forest workers, military personnel, and lab workers. For
other residents of Latvia and travelers to the country, vaccination is also strongly recom-
mended, but not reimbursed, although most private insurance companies cover TBE vaccina-
tion costs.[19, 20] Unfortunately, the impact of these TBE vaccination programs has not been
well documented.
The objective of the current study was to better understand the annual incidence of all TBE
cases officially reported to the CDPC of Latvia since the implementation of TBE vaccine and
TBE serological testing. The study was also done to specifically investigate the burden and clin-
ical characteristics of TBE in Latvia from 2007 to 2016 using the E-CDC case definition. The
results of this study will be the basis for planning and executing a prospective study on the epi-
demiology of TBE in Latvia and also investigating vaccine effectiveness.
Materials and methods
Study design
This was a retrospective database study using officially reported cases of TBE in all age groups,
supplemented by a chart review aiming at identifying additional cases for the period 2007–
2016 in four most significant treatment institutions in Latvia for TBE cases.
TBE case definition
For the period from 1973 to 2006 confirmation of TBE infection in Latvia was largely based on
detection of anti-TBEV-IgM in blood (often in CSF as well), season, tick exposure and clinical
presentation of neurological illness. For nationwide reporting, a TBE case definition has only
been used since 2012. However, for the terms of this study, all TBE cases for the current time
period (2007–2016) were defined following and adapting the E-CDC definition[9]: 1) Clinical
Criteria: Any person with symptoms of inflammation of the central nervous system (e.g. men-
ingitis, meningo-encephalitis, encephalo-myelitis, encephaloradiculitis); 2) epidemiological
link as possible exposure to ‘tick bite in an endemic area’, ‘stay in an endemic area’ (applies to
all patients hospitalized in Latvia) or ‘alimentary exposure’ and 3) Laboratory Criteria (for
Probable case): demonstration of TBE-specific IgM–antibodies in serum sample in a patient
with symptoms of inflammation of CNS as mentioned above; For Confirmed case–usually
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demonstration of TBE specific IgM and IgG antibodies in blood or TBE specific IgM antibod-
ies in CSF in a patient with symptoms of inflammation of CNS.
Study population
The study population consisted of all TBE cases of any age that had ever been reported to the
CDPC of Latvia from 1973 through 2016. Available data from 1973 to 2006 included only the
annual number of TBE cases and thus these data could only be used for TBE incidence analy-
ses. This was due to the limitation that serological confirmation may not always have been
accomplished and that an unknown fraction of patients may only have suffered from a variety
of unspecific symptoms, (e.g. “fever after tick bite”). Case-based data in electronic format were
available as of 2007 and thus the main study population for a more detailed analysis was
defined as reported TBE cases in Latvia from January 2007 through December 2016.
Data collection
The CDPC of Latvia provided all TBE cases from their electronic database to our study investi-
gators at the Riga Stradins University categorized by ICD-10 diagnosis codes for TBE (A84;
A84.0; A84.1; A84.8; A84.9). Hospitals across Latvia were contacted and asked to provide the
respective patient’s case histories/medical records for additional clinical data. Data collection
from patient records was guided by a questionnaire that included information about: age, gen-
der, region of residence, vaccination history (including number of doses received and the vac-
cination date of the most recent dose), tick bite history, exposure to the same identified
infected food source as a confirmed TBE case during an outbreak, clinical symptoms, labora-
tory test results, lumbar puncture results, duration of hospitalization and clinical outcome at
discharge (TBE form). All patient data in data collection process were de-identified.
In total, 26 Latvian hospitals provided TBE case medical records for chart review; one hos-
pital did not share TBE case medical records. In addition, previously unreported TBE cases for
the time period 2007–2016 were found by review of TBE diagnoses according to ICD-10 codes
in four hospital databases. All four hospitals are located in central region of Latvia, Riga. They
include country’s most important multi-profile treatment institution for children–Children’s
Clinical University Hospital, for adults–Riga East Clinical University Hospital and Pauls Stra-
dins Clinical University Hospital and the only specialized treatment institution in Latvia in the
field of infections–Latvian Centre of Infectious Diseases. These cases were also included in the
study population for TBE analysis. Missing or negative results of TBE serology were double
checked at the National Reference Laboratory.
Statistical methodology and analysis
TBE incidence rates from 1973 to 2016 were calculated as the number of cases per 100,000
individuals of the Latvian population by age groups. Population statistics were based on data
from the Central Statistical Bureau of Latvia.
For data collected from 2007–2016 descriptive analyses such as frequency distributions,
percentages, medians and ranges were used to summarize the data (annual incidence of TBE
for each year, age groups, gender, immunization status, region of Latvia, clinical outcome of
the cases etc.). Incidence rates were also summarized by year and age group.
Subjects of any age were included and categorized into two main groups: children (<18
years), and adults (>18 years). More detailed clinical data analyses were performed in three
age groups (<18 years; 18-<60 years; >60 years).
For the period from 2007 to 2016, cases of TBE without serological confirmation (negative
IgM antibodies or missing test results) were excluded from the study. Also patients with
TBE in Latvia
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confirmed TBEV infection (i.e. detection of specific antibodies to the TBEV) presenting to
hospitals with just fever and/or other unspecific possible symptoms of a TBEV-infection but
with no symptoms indicating disease of the CNS (“fever forms”) were identified but excluded
from the current TBE case analysis. However, considering the high prevalence of TBEV infec-
tions among the Latvian population, these cases were collected separately and additional analy-
ses were performed to understand why these cases, despite lack of CNS-symptoms, were
initially considered as TBE and serologically tested.
Definitions
Vaccine failure–TBE in an individual hospitalized (1) at least 2 weeks after the second dose but
before 12 months before the third dose; (2) after the third dose within 3 years before the first
booster; (3) within 5 years after the first of the following booster doses (patients >60 years) or
within 3 years after the first or following boosters in patients age>60 years.
Vaccine ineffectiveness—TBE in an individual who had received an incomplete vaccination
series, specifically (1) only a first dose; (2) only 2 doses and hospitalized less than 2 weeks or
after 12 months after the second dose; (3) the third dose more than 3 years before the first
booster; or after 5 years from the first of the following booster doses (patients >60 years) or
after 3 years from the first or following boosters in patients age>60 years.
Ethical conduct of the study
The study was conducted in full compliance with any legal and regulatory requirements. Ethi-
cal approval of this study was determined by Riga Stradiņš University Ethical Commissions
(September 8, 2016, Nr. 24/08.09.2016.).
Results
Epidemiological data
The total population of Latvia is estimated to be roughly 2 million people (2.416 million in
1973; 1.96 million in 2016).[21, 22] From 1973 through 2016 a total number of 15,193 TBE
cases were reported to the CDPC of Latvia, 2,819 of which were reported from January 2007
through December 2016 (Fig 1), additionally for this time period, a review of four hospital
databases for TBE identified an additional 104 cases that had not been reported to the CDPC
previously (104/2,923 = 3.6%). From all 2,923 reported cases, only 1,973 TBE cases (2007–
2016) met TBE case definition criteria (CNS inflammation signs plus serological confirmation;
as Probable case) and were included in the TBE study analysis. The remaining 950 cases (32%)
were excluded from current analysis and were largely from patients hospitalized with serologi-
cal confirmation of a TBEV infection but without any clinical signs of CNS disease (n = 733;
25%) and with negative/missing serological data (n = 217; 7%).
Annual TBE incidence rates for the 1973–2016 timeframe are displayed in Fig 2. The high-
est average 10 year incidence was observed from 1990–1999 (27.9 cases per 100,000 popula-
tion; range 4.6–53.0) and the average 10-year incidence of TBE from 2007–2016 using the TBE
case definition was 9.6 cases per 100,000 population (range 5.8–14.6). The officially reported
incidence of TBE after implementation of the E-CDC case definition decreased by about 40%
(2011: 19.4 cases per 100,000; 2012: 11.5 cases per 100,000). The highest yearly incidence after
introduction was observed in 2010 (14.6 cases per 100,000), followed by significant decreases
in 2014 (7.0 cases per 100,000; p<0.001) and 2015 (6.7 cases per 100,000). While the annual
incidence shows a general tendency to decrease, an increase was observed in 2016 (10.9 cases
per 100,000) compared to the prior year.
TBE in Latvia
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Pediatric TBE incidence rates between 2007 and 2016 were lower than that of the overall
population (Fig 3). In the last decade, the highest TBE incidence in children was observed in
2012 (5.7 cases per 100,000). This was followed by an almost four fold decrease by 2016 (1.5
cases per 100,000).
TBE incidence from 2007 to 2016 was found to vary between different regions of Latvia
(Fig 4). The highest incidence of TBE over this time was observed in Kurzeme (19.3 cases per
Fig 1. Flow chart of TBE patients selected to the study.
https://doi.org/10.1371/journal.pone.0204844.g001
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100,000) and Vidzeme (12.8 cases per 100,000). The lowest incidence was reported from Lat-
gale (6.8 cases per 100,000) and Zemgale (6.1 cases per 100,000).
Data concerning the onset of TBE country-wide by month were available for 97.8%
(n = 1929) of patients. Most cases were reported in summer months (July: 350 cases [17.7%];
August: 417 cases [21.1%]; September: 398 cases [20.2%]) (Fig 5). In addition, there were outly-
ing cases reported during the winter with 6 cases in December (0.3%), 4 cases in February
(0.2%) and 1 case in March (0.1%).
Patient characteristics
A total 1,973 serologically confirmed TBE cases were reported between 2007 and 2016 according
to the TBE case definition and were analysed for clinical characteristics. Most of the cases were
adults (95.1%; n = 1,877) (Fig 6), and 52.2% of cases were seen in males (n = 1,029). The median
age in the adult population was 49 years (range: 18–91), and the median age in children was 11.5
years (range: 2–17). There were no registered TBE cases in children younger than 2 years.
Fig 2. TBE incidence rates in whole population; 1973–2016; vaccine uptake gradually increased from 39% (2009) to 52% in 2015.
https://doi.org/10.1371/journal.pone.0204844.g002
TBE in Latvia
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The most common clinical form of TBE for children and adults was meningitis (90.6%;
n = 1,787) (Fig 7). Severe forms like meningo-encephalitis and meningo-encephalo-myelo-
radiculitis were seen in 8.9% of patients (n = 174). In 0.6% of cases (n = 12), CNS inflammation
signs were present with unknown clinical form. The median duration of hospitalization was
12 days (range: 1–221 days). A tick bite prior to TBE onset was reported in 60.6% of TBE cases
(n = 1,139). Transmission via unpasteurised goat’s milk was considered a possible route of
TBE transmission in 0.7% of cases (n = 14). Lumbar puncture was done in 85.3% (n = 1,604)
of all TBE cases. CSF pleocytosis (more than 5x106 leukocytes per litre) was observed in 97.6%
(n = 1,563) of all tested patients.
Immunization status
According to hospital records, 1.6% (n = 32) patients had been vaccinated against TBE with at
least one dose. 98.2% (n = 1,937) of patients (2007–2016) were not vaccinated against TBE.
Vaccination status was unknown for 4 (0.2%) patients. Overall, TBE cases were admitted to
Fig 3. TBE incidences in children (<18 years) and adults, 2007–2016, using the E-CDC case definition.
https://doi.org/10.1371/journal.pone.0204844.g003
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hospital a median of 1,051.5 days (range: 8–3,345) after the last TBE vaccine dose administered
(Table 1).
TBE following anti-TBE vaccination occurred in 18 patients after exclusive use of FSME
IMMUN (TicoVac, Baxter; now Pfizer)(56.3% of total vaccinated TBE cases), and 9 patients
after exclusive use of Encepur (Novartis; now GSK)(28.1% of total vaccinated TBE cases). Five
patients who contracted TBE (15.6% of total vaccinated TBE cases) had received mixed vacci-
nation schedules using both Encepur and FSME IMMUN.
Vaccine failures were identified in 34.4% (n = 11) of those TBE cases that had previously
been vaccinated (Fig 8, Table 2). Thus, approximately, 1.1 TBE vaccine failures cases occurred
annually over the 10 year period from 2007 to 2016. Vaccine failure cases were observed in all
age groups: 2 in those aged<18 years (50%), 6 in those aged 18-<60 years (26.1%) and 3 in
those aged>60 years (60.0%). A total of 5 vaccine failures were seen in patients solely vacci-
nated with FSME IMMUN, 1 vaccine failure occurred in a patient solely vaccinated with Ence-
pur and 5 vaccine failures were observed in patients who had received a mixed vaccination
schedule including both vaccines. Vaccine ineffectiveness was seen in 10 TBE cases previously
vaccinated with FSME IMMUN and in 8 TBE cases previously vaccinated with Encepur. The
exact immunization schedule remained unknown in 3 TBE cases previously vaccinated with
FSME IMMUN.
Fig 4. TBE average incidence rate per 100 000 inhabitants by regions of Latvia (period 2007–2016).
https://doi.org/10.1371/journal.pone.0204844.g004
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TBE infections (2007–2016) that did not meet ECDC-TBE case definition
criteria
There were 733 reports of TBE infection between 2007 and 2016 that did not meet the E-CDC
case definition. Such infections represented 27.1% of all serologically confirmed cases of TBEV
infections reported to CDPC between 2007 and 2016. All these patients had fever (“fever
form”), no CNS inflammation signs clinically. Tick bite prior to the onset of symptoms was
noticed in 52.1% of these cases (n = 382), and transmission via unpasteurised goat milk was
considered a possible source of (the asymptomatic) TBE infection in 2.7% of cases (n = 20).
Most of the cases occurred during periods of high tick activity; July (21.0%; n = 154), August
(20.3%; n = 149) and September (16.5%; n = 121).
From all cases initially reported to CDPC, 7.5% (n = 217) did not meet the laboratory case
definition criteria: in 215 cases serology was negative, nevertheless, repeated testing and test
results remained unknown for 2 cases. None of these 217 cases were included in the current
analysis.
Fig 5. Average TBE seasonality by months (period 2007–2016;n = 1929).
https://doi.org/10.1371/journal.pone.0204844.g005
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Discussion
Since TBE became notifiable in Latvia the highest average 10 year incidence was observed
between 1990 and 1999 (27.9 cases per 100,000) (Fig 2). There is no single causal factor that
alone can explain this peak, but rather a complex mix of several factors. One factor that likely
contributed to the peak was high tick activity that may (at least in part) have resulted from
largely abandoning the use of pesticides on farmlands and meadows.[11] Another likely
related factor was an increased exposure to ticks as a result of increased outdoor economic
activities in the wake of the political and socio-economic changes of 1989, nicely summarized
by Sumilo et al.[8] Moreover, with the increased use of serological confirmation of TBE infec-
tions, there may have been increased awareness (and fear) of TBE, resulting in more frequent
testing and the detection of more cases. It remains unknown which proportion of these cases
had CNS involvement. One may speculate from the dataset provided here for the period
between 2007 and 2016 that about one third of cases between 1990 and 1999 represented
“fever forms”, resulting in a peak TBE incidence of about 36 cases per 100,000. Still, this
Fig 6. Number of TBE cases per age group and gender.
https://doi.org/10.1371/journal.pone.0204844.g006
TBE in Latvia
PLOS ONE | https://doi.org/10.1371/journal.pone.0204844 November 13, 2018 11 / 18
incidence is among the highest in the world, and if accurate, may be a consequence of
increased outdoor exposure as discussed elsewhere.[8, 12]
The adoption of the E-CDC case definition for TBE in Latvia in 2012 ensured a specific
assessment of the burden of disease due to TBE and the impact of vaccination. Specifically, the
reported annual TBE incidence markedly decreased by about 40% from 19.4 cases per 100,000
Fig 7. TBE clinical forms by age groups.
https://doi.org/10.1371/journal.pone.0204844.g007
Table 1. Number of vaccine doses administered and median interval of TBE occurrence in any patient with TBE
who had received at least one TBE vaccine dose.




Median interval from last vaccine dose to
hospitalization with TBE
1st dose 3; (9.4%) 3 years (range 2 to 4 years)
2nd dose 9; (28.1%) 2 years (range 5 days to 5 years)
3rd dose 9; (28.1%) 3 years (range 1 to 9 years)
4th dose (1st booster) 6; (18.8%) 2 years (range 2 to 9 years)
5th dose (2nd booster) 1; (3.1%) 5 months
6 and more doses 4; (12.5%) 2 years (range 8 months to 3 years)
https://doi.org/10.1371/journal.pone.0204844.t001
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in 2011 to 11.5 cases per 100,000 in 2012, just one year after the new case definition had been
implemented. Taking away the fever-only cases from 2011, the incidence drops to 13.6 in the
same year. Comparing TBE incidences for longer periods before (2007–2011) and after (2012–
2016) the E-CDC case definition was used in Latvia incidence still dropped by about one third
(from 14.3 to 9.3 cases per 100,000) and was largely comprised of”fever form” cases.
Fig 8. Vaccine outcome in previously vaccinated TBE cases.
https://doi.org/10.1371/journal.pone.0204844.g008
Table 2. Number of “vaccine failures” and “vaccine ineffectiveness” cases of TBE by vaccine doses and product used.
FSME IMMUN Encepur Mixed vaccination
Vaccine failure Vaccine ineffectiveness Vaccine failure Vaccine ineffectiveness Vaccine failure
After 1st dose - 2 cases - 1 case -
After 2nd dose 1 case 4 cases - 4 cases -
After 3rd dose 1 case 3 cases - 3 cases -
After 4th dose (1st booster) 1 case 1 case - - 3 cases
After 5th dose (2nd booster) 1 case - - - -
After 6 and more doses 1 case - 1 case - 2 cases
https://doi.org/10.1371/journal.pone.0204844.t002
TBE in Latvia
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Looking at Fig 2, in the past 7 years the annual incidence of TBE continued to decrease
from 14.6 cases per 100,000 in 2010 to 6.7 cases per 100,000 in 2015. However, in 2016 it
increased again by about one third to 10.9 cases per 100,000 due to an increased number of
TBE cases among the adult population. Heinz et al. suggested that long range-TBE incidences
peak in>5 year cycles.[13] The TBE increase in adults seen in Latvia in 2016 may be the begin-
ning of such a new cycle, particularly in a largely unvaccinated population. The explanation
for generally decreasing TBE incidence in Latvia in recent years could be the increasing vac-
cine uptake due to The National TBE Immunization Program. This program resulted in an
increase in vaccine uptake from 39% in 20095 to 52.5% by 2015.[23] Moreover, TBE vaccine
uptake in children reached 22% nationwide, and as high as 77% in highly endemic areas. This
likely played a role in reducing the proportion of TBE cases among children from 12.5% in
2001 to 3.6% in 2010[7]. Market research data from 2015 shows that FSME-Immun is the
most commonly used TBE vaccine in Latvia with up to 86% market share among those vacci-
nees who received at least one dose of TBE vaccine and who knew which vaccine they had
received.[24]
TBE incidence rates in Latvia also varied by geographic area during the years investigated.
This can perhaps be explained by different factors influencing tick activity/density and degree
of human contact with the tick habitat such as climatic conditions (a gradual decrease of the
influence of oceanic air masses towards the east of country)[25], vegetation peculiarities (pro-
portion of used or abandoned agriculture fields, bushlands, forest types and forest clearances),
and population density differences and human lifestyle modifications. Climatic factors and
human behaviour may also play a role, as warmer summer months may result in more tick
exposure due to increased outdoor activities (collection of mushrooms and berries, etc.).[26]
In addition, epidemiological investigations suggest that 20%-40% of ticks in Latvia were
infected with TBEV, and that ticks in Latvia carried a higher TBEV load than in other endemic
countries.[7] However, a recent study revealed comparatively low TBEV loads in Latvian ticks
during 2014 (3%) and 2015 (2.1%).[27]
The most common clinical manifestation of TBE reported in all age groups was meningitis.
Meningitis is the mildest and most common TBE neurological form also comparing to the lit-
erature data.[7] Most likely also TBE awareness campaigns and society education plays an
important role in early recognition of disease symptoms, therefore patients present more
timely with milder neurological involvement and receive an adequate treatment avoiding fur-
ther disease development. In adults, the more severe TBE forms (meningo-encephalitis,
meningo-encephalo-myelo-radiculitis) were reported somewhat more frequently among
patients >60 years (7.7% in adults 18-<60 years versus 11.9% in those>60 years; p = 0.0012).
It is worth considering that the growing population of “healthy and active elderly” as a relevant
target for vaccination in order to avoid these severe cases. Additionally, this age group faces
the risk of becoming seronegative earlier after vaccination.[16] In the paediatric population
severe forms were reported in 8.3% of cases. Nonetheless, in children TBEV infections may
more frequently cause nonspecific changes that are clinically significant for the individual and
that may result in long-term-sequelae[28], but which are not detected by the current standard
TBE case definition for meningitis/encephalitis as applied here. Although “fever forms” did
not meet E-CDC TBE case definition criteria, additional analysis showed that they were pre-
sented in almost one third of hospitalized patients. However, real estimate of asymptomatic
TBE infections (“fever forms”) cannot be obtained from this study, because only hospital data
were analyzed and patients without neurological symptoms most likely do not require
hospitalization.
The data shown here demonstrate that TBE occurs almost entirely in the unvaccinated pop-
ulation: 98.2% of cases in this analysis were not vaccinated against TBE. As expected, true
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vaccine failure cases did occur, however at a relatively low estimate of 1.1 cases annually
among the total vaccinated population. Further prospective studies are necessary to collect
more precise data about these possible vaccine breakthrough cases and vaccine effectiveness.
Notably, a tick bite prior to the onset of TBE was noticed by just 60.6% of TBE cases. This is
surprising, given Latvia is a country with an assumed high awareness of TBE. Thus, clinicians
must not rule out TBE in patients with CNS disease based on the lack of remembering a tick
bite in an endemic area. Considering this, and following the Austrian example, a Latvian
national TBE immunization program with partial reimbursement and annual vaccination
reminder campaigns may result in a vaccine uptake of>80%. Such a program would reduce
the disease burden in Latvia log fold.
An important limitation of this study was that all included TBE cases were defined as “prob-
able cases” according to E-CDC case definitions based on positive TBEV specific IgM antibod-
ies in serum samples. The lack of retrospective data for other laboratory tests limits the
definition of included TBE cases to “confirmed cases” according to laboratory criteria. Lumbar
puncture was not done in all TBE cases presenting with neurological signs (headache, fever,
positive meningeal symptoms, paresis etc). CSF pleocytosis is a laboratory sign of CNS inflam-
mation, however as this study was retrospective in nature, in some cases clinical criteria for the
diagnosis of TBE was met based only on the typical symptoms of CNS involvement. In some
cases lumbar puncture was done with normal findings, despite the patient having clinical signs
of CNS inflammation. Such confirmed TBE cases with severe neurological involvement, but
without CSF pleocytosis have been described previously.[29] Another limitation to the study
was that patients presenting with “fever form” (lack of signs of CNS inflammation), were not
analyzed further. Patients presenting with fever could have displayed signs of CNS inflamma-
tion and met case definitions for TBE if lumbar puncture was performed. In comparison to
previous literature, we found a higher proportion of cases with meningitis versus encephalitis.
As our study was population based with detailed review of hospital charts, this finding could
be due to reporting bias with respect to more severe cases. In other studies with more severe
cases, encephalitis or meningoencephalitis may be over-represented. As there is a very high
awareness of TBE in Latvia, more testing may be done even in milder forms of the disease. In
addition, there could be differences in TBE virus subtypes or even more virulent strains occur-
ring in Latvia and the Baltics as compared to other parts of Europe. We are currently conduct-
ing a prospective study to confirm our study’s findings.
In summary, the incidence of TBE in Latvia varies annually and is very difficult to predict.
The data presented here suggest that the national TBE immunization program in Latvia may
have already had a detectable impact with case numbers declining, as particularly documented
in children. Vaccination is a very effective prophylaxis against TBE, and immunization against
TBE has been shown to be cost-effective in other European countries like Austria and Slove-
nia.[30, 31] The current TBE case definition and the need to report TBE cases should be rein-
forced among physicians and health care workers alike in order to maintain the validity of the
reported burden of disease in Latvia. In addition, regular TBE awareness campaigns could
encourage the population in Latvia to use protective measures to further control the TBE in
the country, whether they be specific (vaccination) or non-specific (tick-human contact avoid-
ance etc.) in nature.
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